Supernus Pharmaceuticals, Inc. (SUPN) is a publicly traded Healthcare sector company. As of May 21, 2026, SUPN trades at $48.40 with a market cap of $2.81B and a P/E ratio of -96.00. SUPN moved +2.27% today. Year to date, SUPN is -1.44%; over the trailing twelve months it is +46.66%. Its 52-week range spans $29.16 to $59.68. Analyst consensus is strong buy with an average price target of $63.17. Rallies surfaces SUPN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Which politicians traded SUPN stock?
Recent politician trading activity in SUPN includes disclosures from Gil Cisneros. Rallies tracks purchase and sale disclosures, transaction dates, owners, reported amounts, and post-trade performance context.
SUPN Key Metrics
Key financial metrics for SUPN
Metric
Value
Price
$48.40
Market Cap
$2.81B
P/E Ratio
-96.00
EPS
$-0.51
Dividend Yield
0.00%
52-Week High
$59.68
52-Week Low
$29.16
Volume
0
Avg Volume
0
Revenue (TTM)
$776.83M
Net Income
$-29.02M
Gross Margin
89.42%
Congressional Trades in SUPN
Gil Cisneros purchase SUPN on Mar 24, 2025 (amount: $15.00K).
Recent politician trading activity in SUPN includes disclosures from Gil Cisneros. Rallies tracks purchase and sale disclosures, transaction dates, owners, reported amounts, and post-trade performance context.
Does Rallies track congressional trades in SUPN?
Yes. Rallies tracks politician and congressional stock disclosures for SUPN, including reported purchases, sales, dates, owners, and trade amounts when available.
Is SUPN research on Rallies investment advice?
No. Rallies provides research, data, and educational context for SUPN. It does not provide personalized investment advice.
